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Mechanistic and biological characterisation of novel N5-substituted paullones
targeting the biosynthesis of trypanothione in Leishmania
Andrea Medeirosa,b , Diego Benıteza , Ricarda S. Kornc, Vinicius C. Ferreirad, Exequiel Barrerae , Federico
Carrionf, Otto Pritschf,g, Sergio Pantanoe , Conrad Kunickc , Camila I. de Oliveirad, Oliver C. F. Orbanc and
Marcelo A. Cominia
aLaboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay; bDepartamento de Bioquımica, Facultad de
Medicina, Universidad de la Republica, Montevideo, Uruguay; cInstitut f€ur Medizinische und Pharmazeutische Chemie, Technische Universit€at
Braunschweig, Braunschweig, Germany; dInstituto Gonçalo Moniz (IGM), FIOCRUZ, Salvador, Brazil; eBiomolecular Simulations Group, Institut
Pasteur de Montevideo, Montevideo, Uruguay; fProtein Biophysics Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay; gDepartamento
de Inmunobiologıa, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay.
ABSTRACT
Trypanothione synthetase (TryS) produces N1,N8-bis(glutathionyl)spermidine (or trypanothione) at the
expense of ATP. Trypanothione is a metabolite unique and essential for survival and drug-resistance of try-
panosomatid parasites. In this study, we report the mechanistic and biological characterisation of opti-
mised N5-substituted paullone analogues with anti-TryS activity. Several of the new derivatives retained
submicromolar IC50 against leishmanial TryS. The binding mode to TryS of the most potent paullones has
been revealed by means of kinetic, biophysical and molecular modelling approaches. A subset of ana-
logues showed an improved potency (EC50 0.5–10mM) and selectivity (20–35) against the clinically relevant
stage of Leishmania braziliensis (mucocutaneous leishmaniasis) and L. infantum (visceral leishmaniasis). For
a selected derivative, the mode of action involved intracellular depletion of trypanothione. Our findings
shed light on the molecular interaction of TryS with rationally designed inhibitors and disclose a new set
of compounds with on-target activity against different Leishmania species.
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The genus Trypanosoma and Leishmania encompasses parasitic
protozoa that are the aetiological agents of several highly dis-
abling and/or fatal diseases for humans and livestock (e.g. African
sleeping sickness, Chagas’ disease, the different forms of leishman-
iasis, Nagana and Surra disease). These parasites have a unusual
thiol redox system that depends on the low molecular weight
thiol trypanothione [N1,N8-bis(glutathionyl)spermidine, T(SH)2],
which is absent in mammals1. From the pharmacological point of
view, trypanosomatids present another attractive peculiarity; they
lack genes for glutathione reductase and thioredoxin reductase2.
Being devoid of backup pathways to maintain redox homeostasis,
T(SH)2 is pivotal for parasite viability and virulence by providing
reducing equivalents to cope with oxidative stress and sustain
DNA synthesis and repair3. Indeed, most of the drugs used to
treat trypanosomiasis and leishmaniasis are known to directly (e.g.
efluornithine, antimonials, arsenates) or indirectly (e.g. benznida-
zole, nifurtimox and amphotericin) interfere with T(SH)2
metabolism4–7.
The biosynthesis of T(SH)2 is achieved in two consecutive steps
each involving the ligation of a glutathione (GSH) molecule by its
glycine carboxyl group to the free N1 and N8 amine groups of
spermidine (SP). Both reactions are catalysed by the C-terminal lig-
ase domain of trypanothione synthetase (TryS; EC 6.3.1.9), at the
expense of ATP. The indispensability of TryS for the infective form
of Trypanosoma brucei (Tb)8,9, Leishmania infantum (Li)10 and,
more recently, Trypanosoma cruzi (Tc)11 has been confirmed by
means of reverse genetic or chemical inhibition approaches. The
high conservation of the trypanothione system among trypanoso-
matids2,3 suggests that TryS is essential for this protozoan lineage.
The development of TryS inhibitors is rather limited compared to
work done on the metabolically-related enzyme trypanothione
reductase12. Overall, the TryS inhibitors can be grouped in sub-
strate or transition state analogues13,14, natural derivatives15,16
and other synthetic compounds17–19 (Figure 1).
In the search of novel scaffolds targeting TryS inhibition, we
recently reported the identification of a subset of N5-substituted
paullones f7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-onesg
(Figure 1)10,20,21. Substitutions at position N5 of paullones render
them almost inactive against kinases21,22 while the nature of the
substituent conferred species-selectivity towards TryS. Indeed, the
inclusion of a N-(2-methylamino)ethyl)acetamide group on 9-trifluor-
omethyl paullone (FS-554) or 3-chlorokenpaullones (MOL2008)
(Figure 1) produced the most potent inhibitors of LiTryS so far
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reported with an IC50 value of 0.35mM and 0.15mM, respectively
10,20.
In contrast, less polar substitutions (e.g. 3-chlorokenpaullones with
N-benzylacetamide substituent at N5) rendered better and moderate
inhibitors of TryS from T. cruzi (IC50 10mM) or T. brucei TryS (IC50
30mM)21, suggesting species-specific differences at the enzyme
binding site interacting with the N5-group of paullones. The most
active inhibitors of TcTryS (IC50 10mM) allowed the chemical valid-
ation of the enzyme and of T(SH)2 as a key metabolite for T. cruzi
proliferation and drug-resistance11. Similarly, FS-55410 and
MOL200820 displayed on-target effect against the extracellular form
of L. infantum. However, both compounds displayed a high cytotox-
icity towards murine macrophages (selectivity index, SI <1)20, which
clearly indicates that they have additional molecular targets on
mammalian cells.
With the aim to improve the biological selectivity of N5-aceta-
mide substituted paullones and get insights towards mechanistic
aspects of the TryS-inhibition mode, 36 novel derivatives of 3-
chlorokenpaullones were synthesised and tested in vitro against
TryS from different trypanosomatids, and Leishmania species asso-
ciated with visceral and (muco)cutaneous diseases in humans.
Materials and methods
Reagents
Unless otherwise stated all chemical reagents were of analytical
grade and purchased from Sigma-Aldrich (Chicago, IL) and Acros
Organics. Cell culture medium, antibiotics and foetal bovine serum
(FBS) were from GibcoVR or InvitrogenTM (Carlsbad, CA). T(SH)2 and
mono(glutathionyl)spermidine (GSP) were kindly provided by Dr
Luise Krauth-Siegel (Heidelberg University, Heidelberg, Germany).
Synthetic chemistry
Melting points (mp) or decomposition points (dec) were deter-
mined in an open-glass capillary on an electric variable heater
Figure 1. Trypanothione synthetase inhibitors. The structure and biological activities (IC50 against TryS or Ki, EC50 against trypanosomatids and selectivity index) are
shown for representatives singletons or scaffolds reported to inhibit TryS. The data shown in the upper box were reported in14 for phosphinopeptides, in19 for oxabicy-
clo nonanone, in15 for conessine, and in16 for cynaropicrin. Data shown in the middle box was reported in17 for the phenyl-indazole derivative and in18 for the phenyl-
tetrazole and -thiazole derivatives. Lower panel, the 7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-ones core scaffold, referred as paullone, is shown in red.
Incorporation of a Cl and Br atom at position 3 and 9, respectively, give rise to chlorokenpaullone. The asterisk denotes data reported in this work whereas information
for FS-554 f9-trifluoromethylpaullone with N-[2-(methylamino)ethyl]acetamide side chaing and MOL2008 f3-chlorokenpaullone with N-[2-(methylamino)ethyl]aceta-
mide side chaing was reported elsewhere10,20. Compound 20 is a 3-chlorokenpaullone with 2-oxo-2-piperazinoethyl side chain as hydrochloride.
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(Barnstead Electrothermal IA 9100, Electrothermal, Staffordshire,
Great Britain) and were not corrected. KBr pellets were prepared
for the recording of IR-spectra with a Thermo Nicolet FT-IR 200
(Thermo Nicolet, Madison, WI). DMSO-d6 solutions of compounds
were prepared to record the 1H NMR and 13C NMR-spectra on a
Bruker Avance DRX-400 and a Bruker Avance II-600 (Bruker,
Billerica, MA; NMR Laboratories of the Chemical Institutes of the
Technische Universit€at Braunschweig). Chemical shifts were related
to tetramethylsilane (d¼ 0ppm). The CE Instruments
FlashEAVR 1112 Elemental Analyser (Thermo Quest, San Jose, CA)
was used to perform elementary analyse. The MAT95XL spectrom-
eter (Thermo Finnigan MAT, Bremen, Germany; Department of
Mass Spectrometry of the Chemical Institutes of the Technische
Universit€at Braunschweig) was used to perform the EI mass spec-
trometry and the LTQ-Orbitrap Velos (Thermo Fisher SCIENTIFIC,
Bremen, Germany; Department of Mass Spectrometry of the
Chemical Institutes of the Technische Universit€at Braunschweig)
was used to perform the ESI mass spectrometry. The Mass spectra
were recorded on a double-focus sector field mass spectrometer
Finnigan-MAT 90 (EI) or on a linear ion trap coupled with orbitrap
mass analyser (ESI). Accurate measurements were conducted
according to the peakmatch method using perfluorokerosene as
an internal mass reference (EI) or were recorded by direct infusion
in methanol with tetradecyltrimethylammonium bromide (final
concentration 50mg/mL) (ESI); (EI)-MS: ionisation energy 70 eV;
(ESI)-MS: positive modus, 2.3–2.8 V. TLC: PolygramVR Sil G/UV254,
40 80mm (Machery-Nagel, D€uren, Germany), visualisation by UV-
illumination at 254 nm. The purity of 95% was ensured with HPLC
under following conditions, devices and settings: LaChrome EliteVR
(isocratic elution): pump L-2130, column oven L-2300, autosampler
L-2200, diode array detector L-2450, OrganizerBox L-2000, column
Merck LiChroCARTVR 125–4, LiChrospherVR 100, RP-18, 5mM, (Merck/
Hitachi, Darmstadt, Germany); LaChrom EliteVR (gradient elution):
pump L-2130, autosampler L-2200, UV detector L-2400,
OrganizerBox L-2000, column Merck LiChroCARTVR 125–4,
LiChrospherVR 100, RP-18, 5 mM, (Merck/Hitachi, Darmstadt,
Germany); isocratic eluent: acetonitrile/buffer mixture or aceto-
nitrile/water mixture; gradient elution (method A): concentration
acetonitrile 0–2min: 10%, 2–12min: 10% ! 90% (linear),
12–20min: 90%; gradient elution (method B): concentration aceto-
nitrile 0–10min: 10% ! 70%, 10–10.5min: 70% ! 90%,
10.5–22min: 90%; elution rate: 1000mL/min; detection wave-
length: 254 nm and 280 nm (isocratic), 254 nm (gradient); overall
run time: 15min at 40 C (isocratic); tM (DMSO) (dead time related
to DMSO); tMþS (total retention time); wavelength maxima were
extracted from spectra generated by diode array detector during
HPLC analyses; preparation of buffer pH 2.7: To a solution of
20.0mL triethylamine and 242mg sodium hydroxide in 980mL
water, sulphuric acid was added drop wise to reach pH 2.7.
THF was pre-dried over potassium hydroxide and subsequently
distilled from CaH2. CH2Cl2 was dried by distillation from CaH2.
3-Chlorokenpaullone (1) was synthesised in a four-step
synthetic sequence according to a published method23. 2-
(Piperidin-1-yl)ethan-1-amine and 2-morpholinoethan-1-amine
were synthesised according to a method previously reported24.
Tested substituted paullones were synthesised according to
the procedures described in Supplementary Information.
Expression and purification of recombinant TryS
TryS expression and purification were performed according to pro-
tocols previously reported20, except for the size exclusion chroma-
tography. Elution fractions from the metal-affinity chromatography
(60mg for TbTryS and LiTryS and 16mg for TcTryS) were
loaded onto a HiLoadVR 16/60 SuperdexVR 200 pg column (GE
Healthcare, Piscataway, NJ) pre-equilibrated with 100mM HEPES
pH 7.4, 10mM MgSO4, 0.5mM EDTA, 1mM DTT and 150mM NaCl.
The chromatography was performed at room temperature
(20–25 C) using an €Akta-FPLC device (GE Healthcare, Piscataway,
NJ) and a flow rate of 0.75mL/min. The fractions containing
recombinant TryS were pooled, concentrated to 1mg protein/
mL using a 10 kDa cut-off Amicon filter (Millipore, Billerica, CA).
Glycerol was added at a final concentration of 40% (v/v) and sam-
ples stored at 20 C. Enzyme purity and activity were assessed
by SDS-PAGE (12%) under reducing conditions and by the end-
point TryS assay (see below “TryS activity assay”), respectively.
Protein concentration was determined using the bicinchoninic
acid assay with bovine serum albumin as standard. The protocols
described above yielded 4–8mg TcTryS and 25–30mg TbTryS or
LiTryS per litre of culture medium with all enzyme preparations
presenting 95% purity and homogeneous specific activity.
TryS activity assay
TryS activity was determined by the end-point assay20, which is
described below. For all TryS, ATP was used at 150 mM and SP
fixed at 2mM, whereas GSH was adjusted to 0.57, 0.25 and
0.05mM for TcTryS, LiTryS and TbTryS, respectively, to avoid sub-
strate inhibition or to approach physiological concentrations. A
master mix (MM) solution containing all the substrates at 1.25-fold
their end concentration in assay was prepared in the screening
reaction buffer (5mM DTT, 10mM MgSO4, 0.5mM EDTA, 100mM
HEPES pH 7.4). Ninety-six wells microtitre plates were loaded with
5 mL/well of the test compounds, DMSO (reaction control) or TryS-
specific inhibitor (inhibition control), and 40mL of MM. The reac-
tions were started by adding 5 mL of TryS and stopped after
15min with 200 mL BIOMOL GREENTM reagent (Enzo Life Sciences,
Farmingdale, NY). The plates were incubated 20min at room tem-
perature and then A650 nm was measured with a MultiScan EX
plate reader (Thermo Fisher Scientific, Waltham, MA). Blanks were
prepared for each condition by adding 5mL of the screening reac-
tion buffer instead of enzyme. The interference of the compounds
with the colorimetric reaction was evaluated in a sample contain-
ing different concentrations of the compound and 20mM K2HPO4
dissolved in MM. The activity values were corrected accordingly.
All determinations were performed at least by quadruplicates.
Kinetic assays for LiTryS
Assays were conducted at 28 C, using 96-well plates and a total
reaction volume of 50mL, 5 mL of test compound or DMSO and
40 mL of MM. The reactions were started by adding 5 mL enzyme
and stopped after 15min with 200 mL BIOMOL GREENTM reagent.
The colorimetric reaction was allowed to develop for 20min and
then A650 nm was measured with a MultiScan FC plate reader
(Thermo Fisher Scientific, Waltham, MA).
Before running the kinetic studies, the enzyme concentration
was adjusted in order to obtain a linear progression during the
first 15min of reaction under optimal substrates concentration for
LiTryS (13mM SP or 250 mM GSP, 250mM GSH and 200 mM ATP;
data not shown), which corresponded to an enzyme activity of
7.2 106mmol/min mL with SP or 2.1 105mmol/min mL
with GSP.
Compound 20 and MOL2008 were tested at concentrations 1,
2.5, 5, 7.5 and 10 times their IC50. Due to substrate inhibition by
GSH20, the assays were performed at sub-KM [GSH] (from 100 to
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3 mM), whereas SP and ATP were added at 13mM (9.1-fold the
KM value) and 200mM (4.6-fold the KM value), respectively. When
ATP was the variable substrate, the concentrations tested ranged
from 200 to 6 mM, whereas SP and GSH were fixed to 13mM and
250 mM (1.5-fold the KM value), respectively. For SP, the concen-
trations were varied from 13 to 0.41mM, ATP and GSH were fixed
to 200 mM and 250mM, respectively. For GSP, the concentrations
tested were from 250 to 7.8 mM, while ATP and GSH were fixed to
200 mM and 250 mM, respectively.
All tests were performed in quadruplicates for each concentra-
tion of compound evaluated. Blanks were prepared for each con-
dition by adding 5 mL of screening reaction buffer instead
of enzyme.
The assays were run manually and yielded an intra-assay coeffi-
cient variation 2.5%. Lineweaver–Burk plots (1/[Abs] versus 1/
[substrate]) were prepared and analysed using the OriginPro 8
software (SAS Inc., Cary, NC). An R-square (R2) 0.96 was used as
criteria to eliminate outlier’ values and for linear fitting of plots.
Apparent Ki for MOL2008 against LiTryS in the presence of SP
and GSP was determined assuming a pure competitive inhibition25
and employing the equation apparent KM/KM¼ [Inhibitor].Ki1 þ 1.
Isothermal titration calorimetry assay
ITC experiments were conducted by titrating 60mM MOL2008
with LiTryS in its apo- or GSH-bound forms at concentrations of
429 mM and 615mM, respectively, or by titrating 60mM MOL2008
on ADP-bound LiTryS at 6.7mM and ADP/GSH-bound LiTryS at
6.2mM. The first step consisted in buffer exchange of LiTryS in
titration buffer [97.5mM HEPES pH 7.4, 0.49mM EDTA, 9.75mM
MgSO4 and 2.5% (v/v) DMSO] in the absence (apo-form) or pres-
ence of substrate/product: 2mM GSH (5mM DTT) or 2mM GSH/
2mM ADP (5mM DTT). For apo- and GSH-bound LiTryS, an exten-
sive dialysis using a SnakeSkinTM Dialysis Tubing, 3.5 K MWCO,
16mm (Thermo Fisher Scientific, Waltham, MA) was performed for
10 h at 4 C. For GSH/ADP-bound LiTryS, buffer exchange was per-
formed at 4 C by diafiltration on a 10 kDa cut-off Amicon filter
(Millipore, Billerica, CA) and repeated cycles of centrifugation-dilu-
tion at 3500 g (RT1 Thermo-Sorvall centrifuge). Prior to ITC assay,
TryS activity was assayed to estimate the fraction of
active enzyme.
To reduce buffer composition mismatch for both interaction
solutions, MOL2008 was dissolved (final concentration of 60mM)
in the dialysed buffer from the protein sample by sonication at
room temperature for 5min in an Ultrasonic bath (Branson Model
B200), and further incubated 1 h at 37 C. All samples were
degassed immediately before ITC.
The ITC experiments were done at 28 C in a MicroCal VP-ITC
equipment (Malvern Instruments, Malvern, UK) by collecting data
from twenty-seven injections of 10mL (at 0.5mL/s) spaced by peri-
ods of 500 s, to achieve an accurate post injection baseline.
Data analysis was carried out by automated baseline adjust-
ment and heat integration using NITPIC software26,27. Integrated
heat dataset was fitted to an Aþ B<–>AB heterodimer association
model with SEDPHAT28 and plotted with GUSSI29 software.
Molecular simulations
Docking calculations were performed with AutoDock Vina 1.1.230.
Input PDBQT files for the receptors and ligands were prepared
with AutoDockTools 1.5.631. All torsions of the ligand were set as
fully rotatable applying to the receptors a partially flexible treat-
ment, allowing the following side chains to rotate: for Escherichia
coli mono(glutathionyl)-spermidine synthetase (EcGspS): Trp226,
Leu227, Tyr237, Asn241, Gln243, Val244, Ile245, Asn246, Glu341,
Trp349, Glu391, Tyr394, Asp610 and Ile611; and for LmTryS:
Trp234, Leu235, Phe245, Phe249, Val263, Ser264, Glu355, Trp363,
Glu405, Glu407, Tyr410, Asp623 and Phe626. We retained a total
of 15 different binding poses per ligand, setting an energy range
of 5 kcal.mol1. The best binding scoring was of 11 kcal.mol1 cor-
responding to 1 in LmTryS. Subsequent docking scores are pre-
sented as percentages of this reference value. The search space
was defined by a grid with X, Y and Z dimensions of 20 22 36
angstroms. The grid was centred so that the binding pockets cor-
responding to GSH and GSP could be included in the
search space.
The loop comprising Glu248 to Val263 of LmTryS was modelled
with ModLoop32. Three possible conformations were obtained by
changing the starting and ending position of the loop segment
provided to the server.
Multiple sequences analysis
The sequences of L. major, L. infantum, Crithidia fasciculata, T. cruzi
and T. brucei brucei TryS proteins (accession identification num-
bers: CAC83968.1, CAM69145.1, AAC39132.1, AAO00722.1 and
CAC87573.1, respectively) were aligned with Clustal Omega33 tool
from the server of the European Bioinformatic Institute (http://
www.ebi.ac.uk/Tools/msa/clustalo).
Cell culture and cytotoxicity assays
Mouse macrophages from the cell line J774 (ATCCVR TIB67TM) were
cultivated in vented-cap culture flasks (CorningVR ) containing
Dulbecco’s Modified Eagle Medium supplemented with 10% (v/v)
FBS, 10U/mL penicillin and 10mg/mL streptomycin. The cell cul-
ture was incubated in a humidified 5% CO2/95% air atmosphere
at 37 C. Two hundred mL of a cell suspension containing 6 104
cells/mL in fresh culture medium was added per well in a 96-well
culture plate (CorningVR ). Next day, cells were incubated for 24 h
with the selected paullones or the control drug Amphotericin B
(Fungizone, sodium deoxycholate form, GibcoVR , Carlsbad, CA)
added at different concentrations (from 100 to 0.001mM, and
200 mM for 1). Thereafter, cytotoxicity was evaluated using a col-
orimetric assay (WST-1 reagent from Roche, Basel, Switzerland)
and an EL 800 microplate reader (BiotekVR ). The following equation
was used to estimate cytotoxicity: cytotoxicity (%)¼ [(A450 nm for
cells treated with compound X  A450 nm for DMSO-treated cells)/
(A450 nm for non-treated cells  A450 nm for DMSO-
treated cells)] 100.
Leishmania infantum promastigotes (strain MHOM
MA67I7MAP263, wild type: WT or single TryS-knock out cell line:
sKO)10 and L. braziliensis promastigotes (strain MHOM/BR/01/
BA788) were cultured in plug seal-cap culture-flask (CorningVR ) at
28 C in Roswell Park Memorial Institute 1640 Medium containing
GlutaMAXTM, 25mM HEPES sodium salt (pH 7.4) and at 26 C in
Schneider’s medium, respectively. Both culture media were sup-
plemented with 10% (v/v) FBS, 10U/mL penicillin and 10mg/mL
streptomycin.
Macrophages seeded in a 24-well plate containing glass cover-
slips [1 105 cells/mLwell in Dulbecco’s Modified Eagle Medium
with 1% (v/v) FBS] were infected with 2 106 stationary-phase
promastigotes from L. braziliensis or L. infantum
(macrophage:Leishmania ratio of 1:20) for 24 h (2 h at room tem-
perature and 22 h at 35 C for L. braziliensis or at 37 C for L. infan-
tum). Thereafter, the plates were washed with phosphate buffered
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saline (pH 7.0) to remove non-internalized parasites and then
compounds were added at different concentrations (5 or 10mM
for primary screening or 10–0.01mM for EC50 determination). After
24 h incubation at 37 C and 5% CO2, the wells were washed three
times with phosphate buffered saline (pH 7.0), and the cells
attached to the coverslips were fixed (EtOH 100%, 10min) and
incubated with fluoroshieldTM-DAPI mounting medium to stain
nucleic acids. Fluorescence and bright field images from a total of
100 to 200 macrophages distributed in 4 or 5 microscope fields
were acquired with an Olympus IX-81 inverted fluorescence micro-
scope equipped with an ORCA, Hamamatsu camera and the
mManager free software34. The percentage of infected cells by
compound X at concentration Y was calculated as follow: [number
of infected cells treated with compound X at concentration Y/
number of infected cells treated with DMSO 1% (v/v)] 100%. For
all compounds, the end concentration of the vehicle (DMSO) in
the assay was 1% (v/v). The EC50 for Amphotericin B was deter-
mined from drug-response curves for concentrations spanning
from 0.27 to 0.01mM and following the protocol described above.
The negative control corresponded to cells treated with 1% (v/v)
DMSO. Each condition was tested at least in duplicates.
All data corresponding to cytotoxicity or infection assays were
analysed using GraphPad Prism 6 (GraphPad Software, La Jolla,
CA). The EC50 values were determined from concentration–
response curves (up to seven experimental concentrations of com-
pounds were tested in at least duplicate) fitted to a four-param-
eter sigmoid equation or extrapolated from non-linear fitting
plots. All errors are expressed as one SD, estimated as r n–1.
Determination of intracellular low molecular mass thiols
The method is a modified version of that previously described by
Fairlamb et al.35. Leishmania infantum promastigotes from the WT
and sKO cell lines were seeded at 5 105 cells/mL and cultured
for 24 h as described above in the presence of 7 mM 20 or DMSO
1% (v/v). Thereafter, cells were harvested by centrifugation (2000 g
for 10min at room temperature) and low molecular weight thiols
labelled and extracted as described below.
A 50% confluent culture of murine macrophages (cell line
J774) was infected with L. infantum promastigotes (WT and sKO),
from a 24 h stationary-phase culture at a ratio 1:40 (1 106 macro-
phages:4 107 parasites), during 24 h (2 h at room temperature
and 22 h at 37 C). Next, the cell monolayer was washed with
phosphate buffer saline (pH 7.0) to remove extracellular parasites,
and then treated or not with 1 mM 20 for 24 h. Cells were scraped
and harvested by centrifugation (2500 g for 10min at room tem-
perature). Non-infected macrophages were included as control.
All samples (promastigotes or infected macrophages) were
washed twice with phosphate buffered saline (pH 7.0) and resus-
pended at a density  1.0 107 cells/0.1mL of 40mM HEPES pH
8.0, treated during 1 h at room temperature with NaBH4 70mM
(stock 1M in distilled water) and then added of monobromobi-
mane up to 2mM (stock 100mM in ethanol). After incubation at
70 C for 3min, the samples were cooled on ice, then added of
100 mL 4M methanesulfonic acid and incubated overnight at 4 C.
The supernatant containing the derivatized low molecular mass
thiols was centrifuged at 13,000 g for 40min at 0 C. Labelled thi-
ols were separated using solvent A: 0.25% camphorsulfonic acid
pH 2.6 and solvent B: 25% 1-propanol in solvent A, and the fol-
lowing conditions: 100 mL of the sample, corresponding to 
0.5 107 cells, was injected onto a C18, 5mm, 4.6 150mm col-
umn connected to an HPLC (both from Agilent, Palo Alto, CA) pre-
equilibrated in 12% solvent B followed by a linear gradient from
12 to 50% solvent B over 36min at a flow rate of 1mL/min. The
column was calibrated with derivatized standards of GSH and
T(SH)2 in the concentration range of 2.5 to 75 nmol. For the differ-
ent samples, the relative level of these molecular weight thiols
was determined by integrating the corresponding HPLC peak
areas and, when corresponding, subtracting the GSH content con-
tributed by non-infected, non-treated macrophages. For promasti-
gotes, the values for each thiol were expressed as % relative to
non-treated WT cells, whereas for samples from infected macro-
phages, the values were expressed as fold-change normalised
against non-treated samples. At least duplicate assays were per-
formed for each condition and the data were analysed using the
GraphPad Prism 6 programme (GraphPad Software, La Jolla, CA),
applying an unpaired t-test for statistical comparison.
Results
TryS-based screening of N5-substituted paullones
Previous reports show that 3-chlorokenpaullones containing sub-
stitutions at position N5 are species-specific TryS inhibitors10,20,21.
However, the contribution of the paullone scaffold to enzyme
inhibition was unknown. The core scaffold 3-chlorokenpaullone (1)
tested at 30mM proved inactive against Trys from L. infantum
(Table 1) as well as from T. brucei and T. cruzi (Table S1). In con-
trast, a paullone with a small hydroxyethyl group at position N5
(2) displayed low (10–30% inhibition) to moderate (IC50 30 mM)
activity against at least one of the TryS. This result suggests that
the paullone core alone is not a major determinant of
TryS inhibition.
Given the relevance of this finding, a set of derivatives with dif-
ferent substituents consisting of acetic acid and its ester deriva-
tives, acetamides, N-(2-aminoethyl)acetamides or N-(4-
aminobutyl)acetamide (N-acetyl putrescine) were synthesised and
tested against TryS. Overall, the new derivatives proved more
active against the leishmanial (32 out of 36 with IC50 30mM,
Table 1) than towards the trypanosomal TryS (5 out of 36 with
IC50 30mM, Table S1). Based on these results, structure-activity
relationship analysis was performed only for LiTryS.
Comparison of the four linkers shows that an acetic acid side
chain is detrimental for activity (3 inactive at 30 mM) whereas the
switch to a primary acetamide renders an active derivative (7,
IC50¼ 5.1mM). Compared to the simple primary acetamide (7),
paullones with longer linkers and a terminal amine showed a
10-fold increased inhibitory activity (27, IC50¼ 0.3mM and
35, IC50¼ 0.4mM).
Modification of the carboxylic acid of 3 to an acetic acid ester
with methyl (4, IC50¼ 3.0mM), tert-butyl (6, IC50¼ 2.4mM) or, to a
minor extent, with ethyl (5, 36% inhibition at 30 mM) substituents
proved beneficial for anti-LiTryS activity. This indicates that the
negative charge of the acetate substituent may interfere with
paullone binding to the active site.
For paullones containing an acetamide linker, high activities
(IC50¼ 0.5–0.8mM) were observed for derivatives with small N-alkyl
substituents. A secondary amide (N-methylacetamide, 9) as well as
tertiary amides (N,N-dimethylacetamide, 10 and N,N-diethylaceta-
mide, 12) proved active, which implies that an H-bond donor at
this position is not essential for inhibitor-enzyme interaction. The
primary acetamide (7), the acetohydrazide (8) or amino-substi-
tuted paullone (11) and the analogues containing terminal
hydroxyl functions (13, 14) or the bulkier tert-butylacetamide
group (15), retained low mM activity (IC50¼ 1.5–5.2mM). In con-
trast, the activity was significantly impaired for analogues
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containing terminal heterocyclic (i.e. 1,3,4-thiadiazole, 4,5-dihydro-
1,3,thiazole, 1,3-oxazole, IC50¼ 20–30mM for 16, 17, 18, respect-
ively) or phenyl (IC50 30mM for 19) rings.
Compounds where the nitrogen atom of the acetamide linker
is part of a heterocycle, such as the piperazine (20, IC50¼ 0.3mM)
or the 4-methylpiperazine (21, IC50¼ 0.4mM) derivatives, pre-
sented submicromolar activity. In contrast, addition of a bulky
BOC group (22, IC50¼ 30mM) or pyrimidine (23, IC50¼ 12.5 mM) to
the piperazine moiety affected negatively the activity. A low activ-
ity was also observed for a derivative containing a piperidine sub-
stituent (24, 39% LiTryS inhibition at 30mM). On the other hand,
exchange of the piperidine for a smaller pyrrolidine group,
impacted positively enzyme inhibition (25, IC50¼ 0.5mM). An inter-
mediate activity was observed for the derivative containing a mor-
pholine moiety (26, IC50¼ 2.8 mM).
These data suggest that the enzyme binding pocket for the
N5-substituent of paullones allows the accommodation of an
acetamide linker with either smaller and apolar groups (e.g.
methyl: 9 and 10, ethyl: 11, pyrrolidine: 25) or larger (a)polar
groups (e.g. piperazine: 20 or 4-methylpiperazine: 21). Overall,
compounds bearing tertiary amides (N,N-dimethyl: 10 and N,N-
diethyl: 12) were more potent than those with secondary (9, 11,
13–19) or primary (7) amides. In addition, the apolar nature of
relatively smaller substituents appears to be important because
derivatives containing groups with H-bond donors or acceptors
(e.g. a terminal primary alcohol, 1,3,4-thiadiazole, 4,5-dihydro-1,3-
thiazole or 1,3-oxazole: 13, 14, 16, 17 and 18, all with mM IC50)
were less active than those lacking them (e.g. N-methyl, N-ethyl,
N,N-dimethyl, N,N-diethyl and pyrrolidine: 9, 11, 10, 12 and 25, all
with nM IC50).
MOL2008 contains a side chain consisting of an N-[2-(methyla-
mino)ethyl]acetamide and, so far, is the most active representative
within this compound family (IC50¼ 0.15 mM). Modification of the
terminal amine did not prove critical for inhibitory activity,
because analogues with unsubstituted terminal primary amine
(27, IC50¼ 0.3mM) as well as the tertiary amine (N-[2-(diethylami-
no)ethyl]acetamide, 28, IC50¼ 0.5mM) showed IC50 values within
the same order of magnitude as MOL2008. However, amine pro-
tection with a sterically demanding BOC group and the concomi-
tant reduction of its basic properties decreased by almost two
orders of magnitude compound potency (29, 37% LiTryS inhib-
ition at 30mM) when compared to the unprotected amine deriva-
tive (27). Compounds where the nitrogen atom of the
ethylendiamine moiety is part of a 6-membered heterocycle (i.e.
piperidine: 31, IC50¼ 0.8mM and piperazine: 32, IC50¼ 0.6mM) pre-
sented submicromolar activity.
Furthermore, paullones substituted with an ethylmorpholine
moiety (30, IC50 of 3.3mM) or a modified piperazine (4-
Table 1. Inhibition of trypanothione synthetase (TryS) by N5-substituted, 3-chlorokenpaullones.
% TryS inhibition at 30 lMa
or IC50 value (mM)
b,c
N5-linker chain Compound N5-substitution LiTryS
None 1 H NA
2 CH2CH2OH 30
CH2CO-OR1 3 R1 ¼ H NA
4 R1 ¼ CH3 3.0 ± 0.7
5 R1 ¼ CH2CH3 36.2 ± 3.6
6 R1 ¼ tert-butyl 2.4 ± 0.3
CH2CO-NR1,R2 7 R1 ¼ H, R2 ¼ H 5.1 ± 0.5
8 R1 ¼ H, R2 ¼ NH2 4.0 ± 0.5
9 R1 ¼ H, R2 ¼ CH3 0.8 ± 0.1
10 R1 ¼ CH3, R2 ¼ CH3 0.5 ± 0.0
11 R1 ¼ H, R2 ¼ CH2CH3 1.5 ± 0.2
12 R1 ¼ CH2CH3, R2 ¼ CH2CH3 0.5 ± 0.1
13 R1 ¼ H, R2 ¼ (CH2)2OH 2.3 ± 0.3
14 R1 ¼ H, R2 ¼ C-(CH2OH)3 5.2 ± 0.4
15 R1 ¼ H, R2 ¼ tert-butyl 2.3 ± 0.4
16 R1 ¼ H, R2 ¼ 1,3,4-thiadiazol-2-yl 30
17 R1 ¼ H, R2 ¼ 4,5-dihydro-1,3,thiazol-2-yl 30
18 R1 ¼ H, R2 ¼ 1,3-oxazol-2-yl 20.1 ± 1.5
19 R1 ¼ H, R2 ¼ phenyl 30
CH2CO-R1 20 R1 ¼ piperazin-1-yl, hydrochloride 0.3 ± 0.0
21 R1 ¼ 4-methylpiperazin-1-yl 0.4 ± 0.1
22 R1 ¼ 4-BOC-piperazin-1-yl 30
23 R1 ¼ 4-(pyrimidin-2-yl)piperazin-1-yl 12.5 ± 0.2
24 R1 ¼ piperidin-1-yl 38.6 ± 1.3
25 R1 ¼ pyrrolidin-1-yl 0.5 ± 0.2
26 R1 ¼ morpholin-4-yl 2.8 ± 0.7
CH2CO-NH-CH2-CH2-NR1,R2 MOL2008
d R1 ¼ H, R2 ¼ CH3 0.15 ± 0.06
27 R1 ¼ H, R2 ¼ H, hydrochloride 0.3 ± 0.0
28 R1 ¼ CH2CH3, R2 ¼ CH2CH3 0.5 ± 0.1
29 R1 ¼ H, R2 ¼ BOC 36.7 ± 5.9
CH2CO-NH-CH2-CH2-R1 30 R1 ¼ morpholin-4-yl 3.3 ± 0.1
31 R1 ¼ piperidin-1-yl 0.8 ± 0.1
32 R1 ¼ piperazin-1-yl, dihydrochloride 0.6 ± 0.1
33 R1 ¼ 4-methylpiperazin-1-yl 1.1 ± 0.3
34 R1 ¼ 4-BOC-piperazin-1-yl 30
CH2CO-NH(CH2)4-NH-R1 35 R1 ¼ H, hydrochloride 0.4 ± 0.1
36 R1 ¼ BOC 30
aEnzyme inhibition is expressed as % TryS inhibition ± 2rn-1.
bIC50 values with their corresponding standard deviation (± 2r
n-1) are highlighted in bold italics.
cFor compounds inhibiting Leishmania infantum TryS by 50 ± 5% at 30 lM, an IC50 of 30mM is assumed.
dData published in Ref. 20. NA, not active (enzyme activity at 30 lM is > 95%). BOC, refers to a tert-butyloxycarbonyl group.
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methylpiperazine, 33, IC50¼ 1.1 mM and 4-BOC-piperazine, 34,
IC50 30mM) presented comparatively low anti-LiTryS activity.
Finally, a paullone with a long and flexible alkyl linker, an N-
acetyl putrescine, retained nanomolar inhibitory activity against
LiTryS (35, IC50¼ 0.4mM), which is decreased almost 100-fold upon
protection of the terminal amine with a BOC group (36,
IC50 30 mM).
With respect to the trypanosomal TryS (Table S1), few com-
pounds that were moderately active towards LiTryS showed a
similar activity against TcTryS (i.e. 34, IC50¼ 20mM; 36,
IC50¼ 25 mM; 16, IC50¼ 30mM) or TbTryS (19, IC50¼ 30 mM). Few
highly active compounds against LiTryS with an IC50 in the nano-
molar range showed modest activity against TbTryS (12 and 20
both with IC50 30 mM). Despite these examples, the low inhibi-
tory activity of most paullone analogues against trypanosomal
TryS precluded the elaboration of a structure-activity relationship
analysis. On the other hand, the fact that many of the compounds
reported as (highly) active against LiTryS and not or poorly active
against Tb- and TcTryS highlights remarkable species-specific dif-
ferences at the TrySs binding pocket for the N5-substituted moiety
of paullones.
Kinetic inhibition and binding thermodynamics of N5-
substituted paullones to LiTryS
The mechanism that characterise the inhibition of LiTryS by N5-
substituted paullones was studied for two of the most active ana-
logues that harbour structurally unrelated substituents: N-[2-
(methylamino)ethyl]acetamide (MOL2008; Figure 2) and an acetyl
piperazine (20; S1 Figure). For both paullones, the kinetic analysis
reveals a parallel pattern of the double reciprocal plots for ATP
and GSH that is characterised by a decrease in both substrates’ KM
and Vmax at increasing concentrations of inhibitor (Figure 2(A,B)
and Figure S1(A,B)). Such behaviour is compatible with an uncom-
petitive inhibition of LiTryS. This type of inhibition is preceded by
the formation of an enzyme-substrate complex (TryS-ATP, TryS-
GSH and/or TryS-ATP/GSH) prior to binding of the inhibitor to the
active site. In contrast, for both polyamine-based substrates,
namely SP and GSP, the compounds yielded double reciprocal
plots with convergent lines; where increasing concentrations of
inhibitor correlated with increasing apparent KM values for these
substrates and no changes on Vmax (Figure 2(C,D) and Figure
S1(C)). This behaviour corresponds to a competitive inhibition
Figure 2. Mode of Leishmania infantum TryS (LiTryS) inhibition by MOL2008. Lineweaver–Burk reciprocal plots for the LiTryS activity measured at different inhibitor
(black square: 0mM, red circle: 0.15mM, blue triangle: 0.375mM, violet star: 0.75mM, green inverted triangle: 1.12mM and magenta inclined triangle: 1.5mM) and vary-
ing substrate concentrations while maintaining fixed the concentration of the co-substrates (13mM for SP, 200lM for ATP and 100lM GSH). The enzyme velocities
were measured using an end-point assay (see the section Materials and methods for details) and the reciprocal plots are shown for the varying substrate: (A) GSH, (B)
ATP, (C) SP and (D) GSP [mono(glutathionyl)spermidine].
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mechanism. Although we have previously communicated that
MOL2008 competes with SP binding to LiTryS20, our new data
shows that the binding of N5-substituted paullones extents to the
second GSH-binding site of the enzyme independently whether
the substituent is linear or a cycle. In fact, the Ki for MOL2008
with GSP as competing substrate (Ki¼ 59 nM) was nearly two-fold
higher than with SP (Ki¼ 33 nM), which suggests that GSP com-
petes more efficiently than SP against paullone binding.
To get an insight into the thermodynamics of the inhibitor–en-
zyme interaction, ITC assays were performed with MOL2008, as
model paullone, and LiTryS alone or in the presence of the sub-
strate GSH and/or the product ADP. SP and GSP were excluded
from the titration experiments because of the competitive nature
exhibited by MOL2008 towards polyamine substrates. Titration in
the presence of ATP alone or with GSH could not be performed
due to enzyme-catalysed ATP hydrolysis, an exothermic reaction
that overlaps the heat released by the interaction enzyme–inhibi-
tor (not shown). ADP was considered an adequate surrogate of
ATP because, as shown previously, it remains bound to the
nucleotide-binding site of the enzyme (Ki 90mM)
20.
ITC data was fitted to a 1:1 interaction model, which is compat-
ible with the binding of a single molecule of paullone per TryS
subunit20. For apo-LiTryS, the dissociation constant (KD) for the
LiTryS-MOL2008 complex was estimated in 6.5mM with DH and
DS values of 13.3 kcal.mol1 and 20.6 cal.mol1.K1, respect-
ively (Figure 3(A)). In the presence of GSH (2mM), the affinity for
MOL2008 was 3-fold higher (KD¼ 1.9mM; Figure 3(B)) than that
obtained for the apo-form, which suggests a marginal increase in
the affinity for the inhibitor. Accordingly, the DH
(17.0 kcal.mol1) and DS (30.4 cal.mol1.K1) values decreased
maintaining a similar thermodynamic signature (enthalpy driven
association). Next, titration performed in the presence of the non-
hydrolyzable product ADP (2mM) yielded a KD for
MOL2008¼ 52 nM with a similar thermodynamic signature (DH
13.2 kcal.mol1 and DS 10.5 cal.mol1.K1, Figure 3(C)).
Interestingly, the TryS/ADP complex showed a KD for the inhibitor
37- and 125-fold higher than that estimated for the TryS/GSH
complex and apo-TryS, respectively. This clearly indicates a super-
ior affinity of the compound for the nucleotide-bound enzyme.
Finally, titration of the enzyme with MOL2008 in the presence of
both ADP (2mM) and GSH (2mM) yielded a KD¼ 417 nM with
both enthalpic and entropic contributions (less dependent on the
former than in the other cases, DH 7.9 kcal.mol1, with a favour-
able entropic component, DS¼ 2.9 cal.mol1.K1; Figure 3(D)). The
affinity is 4.5-fold higher than that estimated for the TryS-GSH
complex and 8-fold lower than that exhibited by the TryS/ADP
complex. This shows that, to some extent, high GSH concentra-
tions interfere with inhibitor binding to the TryS/nucleotide com-
plex. Such behaviour agrees well with the kinetic analysis
performed with GSP as variable substrate, which suggests that
binding of N5-substituted paullones extents to the second GSH-
binding site of TryS. At saturating concentrations of substrate (e.g.
2mM GSH for ITC), which exert enzyme inhibition20, this site will
likely be partially occupied by GSH and, hence, competing for
paullone binding.
In agreement with the differences in KD values, comparison of
the Gibbs free energy indicates that paullone binding to LiTryS is
thermodynamically more favoured in the following order: TryS/
ADP (DG 10.0 kcal.mol1) 	 TryS/GSH/ADP (DG 8.8 kcal.mol1)
	 TryS/GSH (DG 7.9 kcal.mol1) > apo-TryS (DG
7.2 kcal.mol1). The comparatively less negative TDS values
observed for the titration performed in the presence of ADP
(3.2) and ADP/GSH (0.88) indicate that these ligands may induce
conformational changes in the enzyme that favour inhibitor bind-
ing. The positive DS and the less negative DH for the titration of
the TryS/ADP/GSH complex are compatible with water displace-
ment from the inhibitor binding-site and the establishment of
hydrophobic interactions between TryS and MOL2008. Although
to a significantly minor extent, such phenomenon is also observed
for the complex TryS/ADP/MOL2008.
The kinetic and thermodynamic studies strongly suggest that
the binding site of MOL2008 and 20, at least partially, overlaps
with that of SP and GSP. GspS is an enzyme capable to catalyse
the formation of GSP but not of T(SH)2 due to steric effects that
preclude binding of GSP to the enzyme’s active site36. Thus, we
reasoned that if occupation of the GSP-binding site by N5-substi-
tuted paullones is relevant for TryS inhibition, then GspS should
not be inhibited by these compounds. Confirming our hypothesis,
Figure 3. Isothermal titration calorimetry of Leishmania infantum TryS (LiTryS) with MOL2008. Top plots: baseline subtracted thermogram showing differential heating
power (DP) versus time. Bottom Plots: integrated and normalised heats of injections versus molar ratio fitted to a heterodimer association model with the correspond-
ing residuals plots. (A) LiTryS (429lM) versus MOL2008 (60lM; non-competent fraction of compound ¼ 0.218). (B) LiTryS (615lM), glutathione (GSH, 2mM), DTT
(5mM) versus MOL2008 (60lM; non-competent fraction of compound ¼ 0.329). (C) MOL2008 (60lM) versus LiTryS (6.7lM; non-competent fraction of enzyme ¼
0.459), ADP (2mM). (D) MOL2008 (60lM) versus LiTryS (6.2lM; non-competent fraction of enzyme ¼ 0.386), ADP (2mM), GSH (2mM) and DTT (5mM).
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GspS from the Kinetoplastid Crithidia fasciculata proved refractory
to MOL2008, which caused a minor inhibition (20%) of the
enzyme at the highest concentration tested of 300 mM (see
Supplementary Information for details about protein preparation
and enzymatic assay). This concentration is 2000-fold higher than
that needed to produce 50% inhibition of LiTryS (Table 1).
In summary, binding of N5-substituted paullones to LiTryS: (a)
is enhanced if an ATP- and/or GSH-enzyme complex is pre-formed,
(b) competes with SP- and GSP-binding, (c) involves occupancy of
the second GSH-binding site, and (d) interferes with catalysis.
Binding model and selectivity of N5-substituted paullones for
non-trypanosomal TryS
To get structural insights into the binding mode of N5-substituted
paullones with TryS, molecular models and target sequences
were analysed.
In TryS, the polyamine binding pocket is an open cleft
bounded by flexible loops that allow binding of polyamines of dif-
ferent length and GSP37,38. One important element of this region
is the loop comprising amino acids Glu248 to Val263 (hereafter
loop248-263), which was not solved in the X-ray structure of
LmTryS37 and has been proposed to facilitate GSP binding3,39.
Molecular modelling suggests a large conformational plasticity for
loop248-263. Conformations ranging from completely solvent
exposed to compactly folded can be modelled onto the protein
scaffold without obvious steric impediments (Figure 4(A)). For E.
coli GspS (EcGspS), the segment equivalent to loop248-263 is five
residues shorter and visible from the electronic density36, which
suggests it is a less dynamic element39. Next, comparative docking
experiments on both protein structures with paullones that do
(i.e. MOL2008 and 20) or do not inhibit (1) LiTryS were per-
formed. Docking onto EcGspS reveals that the preferred binding
sites for paullones lie within a region corresponding to the SP
region and in close proximity to loop248-263, while only low energy
Figure 4. Molecular modelling and docking of selected compounds. (A) Cartoon representation of Leishmania major Trypanothione synthetase (LmTryS) bound to ADP
(top), GSH (right) and GSP (left). The green shading represents the volume occupied by the ligands. Three different possible conformations of the loop248-263 (not
solved in the X-ray structure of LmTryS , PDB id: 2VPS) were modeled and are represented by yellow, cyan and red ribbons. (B) Superimposition of the docking solu-
tions for compounds 1, 20 and MOL2008 on the structure of EcGspS (PDB id: 2IOA). The volume of the ligands ADP and a phosphinate inhibitor solved in the X-ray
structure are shown in green. These ligands were removed prior to docking calculations. Spheres represent the position of the N5 nitrogen in each docking pose. The
binding affinities are indicated by colour from red to blue as percentage of the absolute best docking solution. (C) Top: superimposition of the docking solutions for
the three paullones on the X-ray structure of LmTryS. Docking solutions are coloured as in B. The docking was performed in absence of the loop248-263. (D) and (E)
Inset of the best docking solutions for MOL2008 and 20, respectively. Hydrogen bonds are depicted in green dashed lines and p-stacking interactions are represented
with a translucent red surface. (F) Multiple sequence analysis of the segment corresponding to loop248-263 in TryS from different trypanosomatids coloured by conserva-
tion (black and grey background denote aminoacid conservation and homology, respectively, in at least 4 out 5 sequences). From the top to the bottom: TryS from L.
major (LmTryS), L. infantum (LiTryS), Crithidia fasciculata (CfTryS), Trypanosoma cruzi (TcTryS) and Trypanosoma brucei (TbTryS).
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solutions are located towards the GSH region (Figure 4(B)).
Repeating the same calculations on LmTryS (Figure 4(C)) yielded
higher docking affinities (compare Figure 4(B,C)) with docking
solutions shifted towards the GSP region. Despite some degree
of dispersion in the docking poses, all of them are located
mainly in the GSP region. A hallmark of the best-ranked solu-
tions was the presence of p-stacking interactions between the
paullones indole ring and Phe249, alternating hydrogen bonding
between the secondary amines from the N5-substituents with
the Phe626 backbone oxygen, or the acetamide oxygen and
the Trp363 indolic NH (Figure 4(D,E)). While Trp363 is highly
conserved in Kinetoplastids TryS and EcGspS, Phe249 is replaced
by an Asparagine, Leucine or Cysteine in EcGspS, CfGspS40 and
TcTryS (Figure 4), respectively. This provides additional support
for the striking refractoriness of the last two enzymes to inhib-
ition by the model paullone MOL2008 (see previous section
and Table S1). Furthermore, multiple sequence analysis of the
segment corresponding to loop248-263 reveals that this region is
two residues shorter and poorly conserved in trypanosomal TryS
with respect to the highly conserved signature of leishmanial
and crithidial TryS (13 out of 16 residues are strictly conserved;
Figure 4(F)). Adding value to a potential contribution of resi-
dues from this loop to paullone’s TryS species-specificity, CfTryS
was highly sensitive to MOL2008 with an IC50 of 30 nM
41. This
contrasted with the 40–60% inhibition of trypanosomal TryS
achieved by 30mM MOL2008 (Table S1). The putative conform-
ational diversity generated by the flexibility of the loop248-263
hampers the identification of candidate residues for the interac-
tions with paullones. However, the data presented here support
an important role of this loopy region in determining the
selective binding of N5-substituted paullones to TryS.
Phenotypic-based screenings
In South America, the incidence of (muco)cutaneous leishmaniasis
is at least two orders of magnitude higher than that of visceral
leishmaniasis42. Furthermore, L. braziliensis is the species respon-
sible for the vast majority of the reported cases of (muco)cutane-
ous leishmaniasis in this region42. Therefore, the anti-proliferative
activity of a subset of paullones was preliminary tested against
the clinically relevant form (i.e., intracellular amastigote) of L. bra-
ziliensis. For each set of paullones harbouring different N5-linkers
and substituents, the most active ones against LiTryS were
selected for the screening assay (Table 2). The final concentration
of the compounds in the bioassay was 10mM or, for those causing
detachment of the macrophage monolayer, 5 mM. Paullones con-
taining at N5-position a tert-butyl acetate group (6) or an N-alkyl
acetamide linker (9, 10, 12 and 15) proved poorly active in pre-
venting the infection of macrophages with L. braziliensis (72–107%
infection). Similar to the behaviour observed against LiTryS, com-
pounds with an acetamide linker and bearing tertiary amides
(N,N-dimethyl: 10 and N,N-diethyl: 12) displayed, although minor,
anti-leishmanial activity compared to the inactive mono-substi-
tuted derivatives 9 and 15. Notably, compounds for which the
nitrogen atom of the acetamide linker is part of a heterocycle (20,
21, 25 and 26) were more effective in inhibiting macrophage
infection (15–68% infection). Also derivatives with an N-(2-aminoe-
thyl)acetamide side chain lacking (27) or containing terminal alkyl
groups (MOL2008 and 28) displayed similar anti-L. braziliensis
activity (38–68% infection). From the two paullones with an ethyl-
acetamide linker, only the piperidine (49% infection at 5 mM) but
not the piperazine derivative showed anti-leishmanial activity.
Interestingly, the piperazine group incorporated to a shorter acetyl
linker (20) resulted in an analogue with the highest activity (15%
Table 2. Biological activity of N5-substituted, 3-chlorokenpaullones.
N5-linker Compound N5-substitution
Macrophages EC50 (mM) and [SI]
c
% infection by L.
braziliensis at 10 mMa
% cytotoxicity at 100
mMb or CC50 (mM)
Amastigotes
L. braziliensis L. infantum
none 1 H ND 0 at 200 mM
CH2CO-OR1 6 R1 ¼ tert-butyl 89 ± 13 64 ± 0
CH2CO-NR1,R2 9 R1 ¼ H, R2 ¼ CH3 107 ± 2 93 ± 4
10d R1, R2 ¼ CH3 72 ± 4 at 5 mM 21± 1
12 R1, R2 ¼ CH2CH3 82 ± 14 24 ± 8
15 R1 ¼ H, R2 ¼
tert-butyl
104 ± 1 48 ± 8
CH2CO-R1 20 R1 ¼ piperazin-1-yl,
hydrochloride
15 ± 1 at 5 mM 8.1 ± 0.1 0.2-0.4e [21] 0.9 ± 0.1 [9]
21 R1 ¼ 4-
methylpiperazin-
1-yl
65 ± 7 35.5 ± 0.1 7.0 ± 1.3 [5] 1.0 ± 0.5 [35]
25 R1 ¼ pyrrolidin-1-yl 68 ± 8 69 ± 0
26 R1 ¼ morpholin-4-yl 29 ± 3 10.2 ± 0.2 1.6 ± 0.6 [6] 0.5 ± 0.1 [20]
CH2CO-NH-CH2-
CH2-NR1,R2
MOL2008 R1 ¼ H, R2 ¼ CH3 52 ± 10 10.3 ± 0.1  4 [2.5]  10 [1]
27 R1, R2 ¼ H,
hydrochloride
68 ± 1 36 ± 1
28 R1, R2 ¼ CH2CH3 38 ± 1 at 5 mM 6.0 ± 1.0 3.0 ± 0.5 [2]
CH2CO-NH-CH2-
CH2-R1
31 R1 ¼ piperidin-1-yl 49 ± 3 at 5 mM 9.0 ± 1.0 4.1 ± 0.6 [2]
32 R1 ¼ piperazin-1-yl,
dihydrochloride
139 ± 2 24 ± 3
CH2CO-NH(CH2)4-
NH-R1
35 R1 ¼ H,
hydrochloride
116 ± 3 0
Amphotericin B 8.9 ± 0.5 0.2 ± 0.0 [59] 0.1 ± 0.0 [100]
aPercentage of Leishmania braziliensis-infected macrophages treated with the corresponding paullone at, unless otherwise stated, 10mM. The values are expressed
relative to infected and non-treated macrophages. ND: not determined.
bPercentage cytotoxicity against non-infected macrophages of paullones at, unless otherwise stated, 100 mM. The values are expressed relative to non-treated macro-
phages. CC50 and the corresponding standard deviation (±r
n–1) are highlighted in bold italics.
cSI, selectivity index determined as the ratio EC50 for amastigotes/CC50 for macrophages.
dThe CC50 could not be determined because this compound induced macrophage detachment from the culture surface.
eEC50 interval with 95% confidence.
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infection at 5 mM). In contrast to the paullones with a short alkyl
linker (N-(2-aminoethyl)acetamide; MOL2008, 27 and 28), a
derivative harbouring a longer N5-extension and a terminal amine
(i.e. N-(4-aminobutyl)acetamide, 35) was inactive at 10mM.
Based on the analysis of host cell viability, paullones can be
grouped according to the following degree of cytotoxicity: CC50
>200 mM (1), CC50 100 mM (10, 12, 15, 27, 32 and 35), CC50
100 mM (6, 9, 21 and 25) and CC50  10mM (20, 26, MOL2008,
28 and 31). Thus, except for 35, the incorporation of an
N5-substitution to the core scaffold (1) conferred cytotoxicity to
paullones. On the other hand, paullones showing high activity
against the intracellular stage of L. braziliensis were also the most
cytotoxic towards macrophages (CC50 10mM for 20, 26,
MOL2008, 28 and 31).
The EC50 against L. braziliensis amastigotes was determined for
paullones showing capacity to lower the infection rate at values
65%. Compound 20 represented the most active derivative with
a submicromolar EC50 (value of 0.2–0.4mM) and SI  21, whereas
the potency of the remaining compounds ranged from 1.6 to
7 mM and their SI from 2 to 6. Interestingly, the switch from a ter-
minal secondary (i.e. 20) to a tertiary amine (N-methylpiperazine
moiety, 21: EC50 of 7 mM and SI of 5) affected negatively the
potency and selectivity. Overall, the derivatives consisting of an
acetyl linker substituted with heterocyclic rings (20, 21 and 26)
appeared more selective than those containing a N-(2-aminoethy-
l)acetamide linker substituted with further alkyl groups (MOL2008
and 28) or a heterocyclic ring (31). To assess a potential wide
spectrum activity of the new paullones, the compounds with SI
>2 towards L. braziliensis were tested against a species respon-
sible for visceral leishmaniasis. All three derivatives based on paul-
lones with an acetyl linker substituted with heterocyclic rings (20,
21 and 26) were more active and selective (EC50¼ 0.5–1 mM and
SI¼ 9–35) against L. infantum amastigotes than MOL2008
(EC50¼10mM and SI¼ 1).
In summary, the incorporation of cyclic substituents at the N5-
position yielded analogues with higher and more selective anti-
leishmanial activity than those containing linear substituents.
On-target effect of compound 20
For paullones containing a N-[2-(methylamino)ethyl]acetamide
substituent at position N5, their on-target effect against the pro-
mastigote stage of L. infantum was demonstrated previously10,20.
Here, we extended the study to 20, a derivative with an acetylpi-
perazine substituent. Intracellular thiols were measured in L. infan-
tum promastigotes (Figure 5(A)) and intracellular amastigotes
(Figure 5(B)) from the wild-type and TryS-single KO cell lines
exposed for 24 h to the compound’ EC50 determined for each
parasite stage.
For non-treated promastigotes, and in agreement with the
reduced expression of TryS from the single encoding allele10, the
content of T(SH)2 in sKO cells was about one quarter (24%) of that
present in WT cells (Figure 5(A)). Although to a minor extent, sKO
cells also showed a lower GSH content (63%) compared to WT
cells. Treatment with 20 (7 mM) produced a significant depletion
of T(SH)2 in WT (88% decrease) and in sKO cells, where it became
undetectable [detection limit of 0.5 nmol T(SH)2/100 million cells].
Overall, the metabolic changes induced by 20, namely depletion
of GSH and T(SH)2, resemble those caused by MOL2008 in L.
infantum promastigotes20.
For amastigotes, and compared to non-treated controls, 20 led
to a significant accumulation of GSH in WT (16-fold) and sKO (10-
fold) parasites, respectively (Figure 5(B)). This suggests a differen-
tial metabolic regulation of GSH in non-infective and infective
parasite stages. In contrast, the intracellular content of T(SH)2 was
depleted about 40% in WT and 82% in sKO amastigotes with
respect to the corresponding non-treated controls. This resembles
the metabolic phenotype of bloodstream African trypanosomes
with downregulated expression of TryS8.
In summary, the metabolic changes exerted by 20 in both life
cycle stages of L. infantum are compatible with TryS inhibition.
Discussion
Historically, paullones belong to a series of molecules reported as
inhibitors of mammalian CMGC superfamily protein kinases43–46.
Figure 5. On-target effect of compound 20 in promastigotes and amastigotes of Leishmania infantum. (A) L. infantum promastigotes from the wildtype (WT) or TryS
single knockout (sKO) cell line were incubated for 24 h in the absence (white bars) or presence of 7mM 20 (black bars). The content of free glutathione (GSH) and try-
panothione [T(SH)2] is expressed as % relative to samples from non-treated WT parasites.  and , denote p values < 0.025 and ¼ 0.0052, respectively (two-tailed t-
test). (B) Murine macrophages (cell line J774) infected with L. infantum amastigotes from the WT and sKO cell lines were incubated for 24 h in the absence (white
bars) or presence of 1mM 20 (black bars). The results are expressed as relative fold-change in GSH and T(SH)2 content with respect to the corresponding non-treated
control from each sample. , denotes a p values  0.001 (two-tailed t-test).
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Considering that paullones interfere with the activity of several
kinases that regulate multiple biochemical and biological proc-
esses in cells47–49, the development of selective inhibition against
specific targets represents a challenge. In this regard, structural
analysis revealed that hydrogen bonding to the lactam nitrogen
at position 5 (N5) of an alsterpaullone is necessary for inhibitor
binding to the ATP binding site of GSK-3b22,50. This led to
the assumption that N5-substituted paullones will lose affinity for
kinases, a hypothesis that was confirmed with a subset of 3-chlor-
okenpaullones with N-benzylacetamide substituent at N5 showing
potent and selective anti-T. b. brucei activity and lack of inhibition
of mammalian kinases at 10mM (e.g. compound 3a)21. Further evi-
dence that attainment of selectivity is possible within the paullone
scaffold was provided by the inclusion of a N-[2-(methylamino)e-
thyl]acetamide side chain on position 5 of 9-trifluoromethyl paul-
lone (FS-554) or 3-chlorokenpaullones (MOL2008), which yielded
potent and selective inhibitors of L. infantum TryS (IC50¼ 0.35mM
and 0.15 mM, respectively)10,20. The almost 100-fold lower activity
of these compounds against trypanosomal TryS posed the ques-
tion about the molecular determinants of such selectivity. On the
other hand, the poor biological discriminatory activity of these
paullones suggests that modification of the N5-position, although
detrimental for kinase inhibition, may confer them new molecular
targets in the host cell.
Thus, in an attempt to extend and improve the selectivity of
paullones towards trypanosomal TryS and the clinically relevant
stages of different trypanosomatid species, novel N5-substituted
analogues of 3-chlorokenpaullones were synthesised and charac-
terised. From the 36 new derivatives, 12 of them showed submi-
cromolar activity against LiTryS. However, none of the new
compounds surpassed the potency of MOL2008 against LiTryS
neither extended the selectivity towards trypanosomal TryS. In
fact, the IC50 for the best inhibitors of T. cruzi and T. brucei TryS
were yet two orders of magnitude higher than those obtained
against LiTryS. This likely suggests steric restrictions at the binding
site of paullones to trypanosomal TryS that probably extent
beyond the nature of the N5-substituent. Strategies to overcome
this limitation may include the simplification of the paullone scaf-
fold to reduce compound size while keeping a variety of the link-
ers tested here and in other analogues21 that, as shown here,
appear important for anchoring the paullone to the polyamine
binding site.
The inhibition mechanism of N5-substituted paullones against
LiTryS has been elucidated for the first time. Two compounds har-
bouring structurally unrelated linkers at N5 position showed
uncompetitive inhibition for the nucleotide ligand and GSH, and
competitive for SP or GSP. The ATP-uncompetitive inhibition of
TryS by kenpaullones seems atypical, because it has been well
documented that related analogues behave as ATP-competitive
inhibitors of CDK1/cyclin B43 and GSK-3b50. However, our mechan-
istic observations are fully compatible with the molecular and
binding energy models that support anchoring of the N5-substitu-
ent to the polyamine pocket of TryS whereas the paullone ring
occupies, partially, the polyamine binding site and the second
GSH binding site. In this binding conformation, the paullone scaf-
fold sits away from the nucleotide and first GSH binding sites,
and, hence, does not interfere or compete with their binding to
TryS. Also, biophysical characterisation of the interaction of TryS
with the inhibitor and different physiological ligands yielded data
in line with the inhibition kinetics and binding model. Compared
to the apo-form, the affinity of the enzyme for the inhibitor
increased in the presence of ADP alone (125-folds) or in combin-
ation with GSH (37-folds). In comparison, titration performed at
high concentration of GSH alone (2mM) increased only marginally
(3-folds) the affinity of the enzyme for the paullone. This behav-
iour may have two possible explanations that are not mutually
exclusive: (i) the conformational changes induced by substrate
binding, which subsequently favour paullone interaction with
TryS, are more prominent for the nucleotide than for the thiol
substrate, and (ii) at the saturating concentration of GSH used in
the ITC assay, this ligand may compete with paullone for binding
to the second GSH site within the GSP-binding pocket.
The relevance of the second GSH-pocket for paullone binding
to TryS was further evidenced by the refractoriness of the related
enzyme GspS, which lacks this site, to inhibition by the model
paullone MOL2008. Furthermore, within this region, we have
identified a non-structured element (loop248-263) that may contrib-
ute to the selectivity displayed by paullones for leishmanial and
crithidial TryS. This element is two amino acids shorter in trypano-
somal TryS and has low amino acid sequence conservation with
respect to the highly conserved motif present in leishmanial and
crithidial TryS. Analysis of point mutants of this region may shed
light onto the specific role of individual residues for loop conform-
ation and paullone interaction. This information would be highly
valuable for the rational design of compounds with broad selectiv-
ity for TryS.
In regard to the biological performance of the new derivatives,
and compared to the reference molecule MOL2008, several of
them showed higher potency (from 2.5- to 28-fold) and selectivity
(from 5- to 35-fold) against pathogenic Leishmania that causes
mucocutaneous (L. braziliensis) and visceral leishmaniasis (L. infan-
tum). The derivatives containing a N5-acetamide substituent with
a terminal heterocycle (i.e. piperazine: 20, 4-methylpiperazine: 21
and morpholine: 26) are the most representative examples from
this successful optimisation strategy. This suggests, that in com-
parison to derivatives containing linear alkyl substituents, the het-
erocyclic ring at N5-position is detrimental for the interaction of
paullones with hosts molecular targets. Moreover, the on-target
effect of 20 was confirmed in both life cycle stages of different L.
infantum cell lines.
As shown here, N5-substituted paullones are uncompetitive
inhibitors of TryS with respect to ATP and GSH. Uncompetitive
and mechanistic-based inhibitors are the most wanted, albeit
rarely found, hits in screening campaigns since their design usu-
ally requires several rounds of hit optimisation. In an in vivo con-
text, uncompetitive inhibition is not overcome, but enhanced, by
substrate accumulation because the enzyme/ligand equilibrium is
shifted to the formation of the enzyme–substrate complex for
which the uncompetitive inhibitor has a higher affinity51.
Probably, the higher potency of MOL2008 and 20 towards intra-
cellular amastigotes than against extracellular promastigotes is in
part exacerbated by the significant accumulation of GSH.
The results presented here should contribute to a better under-
standing of TryS molecular features and interaction with inhibitors,
while providing a rationale platform for the design of improved
inhibitors against this top drug target candidate. Future studies
will address the pharmacological potential of the most potent and
selective N5-substituted paullones in a murine model of cutaneous
leishmaniasis.
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